Stock Research for AMGN

AMGN

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

AMGN Stock Chart & Research Data

The AMGN chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the AMGN chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


AMGN Due diligence Resources & Stock Charts

The AMGN stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View AMGN Detailed Price Forecast - CNN Money CNN View AMGN Detailed Summary - Google Finance
Yahoo View AMGN Detailed Summary - Yahoo! Finance Zacks View AMGN Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View AMGN Trends & Analysis - Trade-Ideas Barrons View AMGN Major Holders - Barrons
NASDAQ View AMGN Call Transcripts - NASDAQ Seeking View AMGN Breaking News & Analysis - Seeking Alpha
Spotlight View AMGN Annual Report - CompanySpotlight.com OTC Report View AMGN OTC Short Report - OTCShortReport.com
TradeKing View AMGN Fundamentals - TradeKing Charts View AMGN SEC Filings - Bar Chart
WSJ View Historical Prices for AMGN - The WSJ Morningstar View Performance/Total Return for AMGN - Morningstar
MarketWatch View the Analyst Estimates for AMGN - MarketWatch CNBC View the Earnings History for AMGN - CNBC
StockMarketWatch View the AMGN Earnings - StockMarketWatch MacroAxis View AMGN Buy or Sell Recommendations - MacroAxis
Bullish View the AMGN Bullish Patterns - American Bulls Short Pains View AMGN Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View AMGN Stock Mentions - StockTwits PennyStocks View AMGN Stock Mentions - PennyStockTweets
Twitter View AMGN Stock Mentions - Twitter Invest Hub View AMGN Investment Forum News - Investor Hub
Yahoo View AMGN Stock Mentions - Yahoo! Message Board Seeking Alpha View AMGN Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for AMGN - SECform4.com Insider Cow View Insider Transactions for AMGN - Insider Cow
CNBC View AMGN Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for AMGN - OTC Markets
Yahoo View Insider Transactions for AMGN - Yahoo! Finance NASDAQ View Institutional Holdings for AMGN - NASDAQ


Stock Charts

FinViz View AMGN Stock Insight & Charts - FinViz.com StockCharts View AMGN Investment Charts - StockCharts.com
BarChart View AMGN Stock Overview & Charts - BarChart Trading View View AMGN User Generated Charts - Trading View




Latest Financial News for AMGN


Biogen Expected to Report Robust Rise in Diluted EPS in 2018
Posted on Friday August 17, 2018

In its Q2 2018 earnings conference call, Biogen (BIIB) updated its 2018 GAAP EPS guidance from the previously projected range of $22.20–$23.20 to $21.80–$22.40, which implies a YoY (year-over-year) rise of 83%–87%.


Biogen Expected to Report Robust Revenue Growth in 2018
Posted on Friday August 17, 2018

In its Q2 2018 earnings conference call, Biogen (BIIB) updated its 2018 revenue guidance from the previously projected range of $12.7 billion–$13 billion to $13 billion–$13.2 billion, which would imply a YoY (year-over-year) rise of 6%–7.5%. Wall Street analysts have projected Biogen’s 2018 revenues at $13.2 billion, which would be a YoY rise of 7.5%. Its peers Gilead Sciences (GILD), Amgen (AMGN), and Celgene (CELG) are expected to report revenues of $21.4 billion, $23.1 billion, and $15.1 billion, respectively, in 2018.


Considering Allergan’s Q2 2018 Revenue Trend
Posted on Friday August 17, 2018

As discussed earlier, Allergan (AGN) reported a 2.9% rise in its YoY (year-over-year) revenue to $4.1 billion in the second quarter compared to $4.0 billion in the second quarter of 2017.


Analyst Recommendations for Biogen and Its Peers in August
Posted on Friday August 17, 2018

On July 25, Biogen (BIIB) and Eisai announced positive results from the Phase 2 study evaluating BAN2401, an investigational anti-amyloid-beta (or Aβ) protofibril antibody, in early Alzheimer’s disease (or AD) indication after 18 months of therapy. The patients also included those suffering from AD-related mild cognitive impairment as well as those with mild AD. The results from the Phase 2 trial seem to validate beta-amyloid as a potential target for treating Alzheimer’s disease.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.